@LiverFellow

Collaborative online learning for trainees interested in hepatology | Founded by @hershshroff @LizzieAbyMD @paritapatelmd @adam_c_winters @alexsvogel | #MedEd

liverfellow.org
Joined April 2020
  • Tweets1.8K
  • Following274
  • Followers10.9K
526Media
Excited to introduce the 2026–2027 Liver Fellow Network Leads! 🎉 Driven by a shared commitment to hepatology education and collaboration, we are looking forward to a year of learning and advancing our global liver community together 🌍 #LFN #LiverTwitter #MedEd @AASLDtweets
16
4
50
12,759
🏀 Next up: Surviving HCC—Curative Treatment, Transplant Benefit and Access @akusnik explores which treatments are associated with longer survival, who benefits most from transplant, and who gets access. Thread 👇 #HepMadness2026
4
5
10
676
5/5 Does Surviving HCC make your next round—or take the title? 🏆 Submit your bracket by Oct 31: tourneytopia.com/aasld/hepma… @LTxJournal @HepCommJournal @aasldtweets #HepMadness2026
1
131
4/5 The challenge: All three studies were retrospective, so associations don’t prove causation. The long-term survival study also had potential immortal-time bias. Black patients had lower odds of transplantation, highlighting persistent inequities in access.
13
3/5 The evidence: • 1,191 patients: curative treatment linked to better survival in early-stage HCC. • 36,634 candidates: higher tumor burden linked to greater estimated transplant benefit. • 249,600 patients: LT strongly associated with survival of at least 10 years.
21
2/5 Why it’s a title contender: Improving HCC survival means choosing effective treatment and ensuring patients can access it. This theme connects stage-appropriate care, tumor burden, transplant benefit, and disparities in access.
18
🏀 Next up: Falls, Frailty, and Sarcopenia Sirisha Gaddipati explores how physical frailty, muscle loss, and fall risk affect outcomes in cirrhosis. Can this theme stand strong through the competition? 👇 #HepMadness2026
4
8
14
1,229
5/5 Does this theme earn a spot in your next round? 🏆 Explore the evidence and submit your bracket by Oct 31: tourneytopia.com/aasld/hepma… @LTxJournal @HepCommJournal @aasldtweets #HepMadness2026
2
2
339
4/5 The challenge: Frailty and sarcopenia aren’t interchangeable. Studies used differing definitions, and sarcopenia’s independent association with decompensation was inconsistent. Standardized assessments and prospective studies are needed.
27
3/5 The evidence: • 127 hospitalized patients: frailty predicted lower transplant-free survival (HR 2.22). • Systematic review: sarcopenia was common but inconsistently predicted first decompensation. • 42,046 patients: prior falls strongly predicted future falls (HR 5.69).
20
2/5 Why it’s a title contender: Assessing cirrhosis goes beyond liver-related laboratory results. Recognizing frailty and fall risk could help identify vulnerable patients and guide supportive care before further complications develop.
1
36
Liver Fellow Network retweeted
Vinay Jahagirdar
@vinayjahaOct 24
Is there a better way to catch up on the most practice-changing hepatology research? 📚 1. Go to 🔗tourneytopia.com/aasld/hepma… 2. Click on each theme to read summaries of handpicked studies prepared by Team @LiverFellow 🔍 3. Pick the most influential, submit your bracket by Oct 31, and may the best research win! 🔥 #HepMadness2026 #MedEd @AASLDtweets @DBrandmanMD @Dr_NOvchinsky @Bubu_Banini @ruben_hernaez @ebtapper
7
1
19
2,021
Liver Fellow Network retweeted
Elliot Tapper@ebtapperOct 24
The best game in hepatology is back: HepMadness Fill out your bracket: tourneytopia.com/aasld/hepma…
1
12
15
2,523
🏀 Next up: Expanding the Donor Pool—DCD, Marginal Grafts and Retransplantation @elmasrysan8363 explores how machine perfusion could help us use more donor livers while improving transplant outcomes. Thread 👇 #HepMadness2026
4
5
7
863
5/5 Is expanding the donor pool your championship pick? 🏆 Explore the evidence and submit your bracket by Oct 31: tourneytopia.com/aasld/hepma… @LTxJournal @HepCommJournal @aasldtweets #HepMadness2026
2
4
261
4/5 The challenge: These retrospective studies show associations. Only 100 retransplant recipients received machine perfusion, and infection burden remained higher in the HOPE-DCD cohort. Can the promise of broader graft use carry this theme to the next round?
20
3/5 The evidence: • 979 DCD transplants: NMP associated with less AKI at 48 hours (OR 0.65). • 300 transplants: HOPE-preserved DCD recipients had more infections but similar 1-year survival to DBD recipients. • 1,754 retransplants: perfusion linked to lower 1-year mortality
18
2/5 Why it’s a title contender: Expanding the donor pool means making more grafts usable and understanding their risks. This theme examines kidney injury after DCD transplantation, infection outcomes, and machine perfusion in retransplantation.
39
🏀 Next up: Immunosuppression and Metabolic Management After Liver Transplantation Kyle Yuquimpo explores how to protect the graft while preserving kidney function and improving metabolic health. Thread 👇 #HepMadness2026
4
7
16
1,036
5/5 Is this your championship pick? 🏆 Explore the evidence and submit your bracket by Oct 31: tourneytopia.com/aasld/hepma… @LTxJournal @HepCommJournal @aasldtweets #HepMadness2026
1
5
208
4/5 The challenge: The dialysis trial had a small control arm. Biopsy-guided strategies and GLP-1 findings need larger trials, while promising rejection biomarkers need external validation. Can personalized post-transplant care take this theme to the next round?
47
3/5 The evidence: • RCT, 70 recipients: 24-week dialysis independence 73% with basiliximab + delayed tacrolimus vs 75% with standard care. • Biopsy-guided CNI reduction preserved kidney function. • GLP-1 RAs: modest weight and HbA1c reductions, without a rejection signal.
27
Load more